EB103 + Oncolytic Virus
Multiple Solid Tumors
Discovery/PreclinicalNot yet in clinical trials
Key Facts
Indication
Multiple Solid Tumors
Phase
Discovery/Preclinical
Status
Not yet in clinical trials
Company
About Estrella Immunopharma
Estrella Immunopharma's mission is to extend the curative power of T-cell therapies to a broader range of cancers and autoimmune diseases by addressing the critical limitations of current CAR-T products. The company has achieved an 83% overall response rate in a proof-of-concept study for B-cell lymphoma with its lead ARTEMIS candidate, EB103, and reported no severe CRS. Its strategy involves first advancing its CD19-targeted programs in hematologic malignancies, then leveraging a unique oncolytic virus-based 'mark-and-kill' platform to tackle the vast solid tumor market, while also exploring applications in autoimmune conditions like lupus.
View full company profileTherapeutic Areas
Other Multiple Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| CLD-401 | Calidi Biotherapeutics | IND-Enabling |
| Early Cancer Detection Platform | Astrin Biosciences | Pre-clinical |
| ABC (²¹²Pb-undisclosed) | ARTBIO | Discovery |
| SonoLeukin™ | Vesselon | Pre-clinical |
| ELEPHAS-04 (Mayo Clinic) | Elephas Biosciences | Observational |
| Zimberelimab (AB122) | Arcus Biosciences | Phase 3 |
| ORIC-101 | ORIC Pharmaceuticals | Phase 1b |
| MGC026 | MacroGenics | Phase 1 |
| MGC028 | MacroGenics | Phase 1 |
| MGC030 | MacroGenics | Preclinical |